Comparative Assessment of Nanocrystal and Inclusion Complex Technologies for Solubility Enhancement of BCS Class II Drug Molecules

Abstract

A large proportion of new chemical entities entering pharmaceutical development pipelines exhibit poor aqueous solubility while retaining high intestinal permeability, placing them in Biopharmaceutics Classification System (BCS) Class II. For these molecules, dissolution rather than membrane permeation is the rate-limiting step governing oral absorption, making solubility- and dissolution-enhancing formulation strategies central to clinical success. Among the technologies available, drug nanocrystal engineering and cyclodextrin-based inclusion complexation represent two of the most extensively validated and commercially translated platforms. This review provides a comparative, evidence-based assessment of both technologies across mechanism of action, preparation methodology, physicochemical performance, regulatory track record, manufacturing scalability, and cost. Nanocrystals exploit the relationship between particle size and saturation solubility described by the Ostwald–Freundlich equation, achieving substantial dissolution-rate enhancement through increased surface area while preserving the crystalline, carrier-free nature of the drug; several products (Rapamune®, Emend®, Tricor®, Megace ES®) are commercially marketed using this approach. Inclusion complexation relies on host–guest molecular encapsulation within the cyclodextrin cavity, offering high reproducibility, well-characterized regulatory precedent, and ancillary benefits such as photostability and taste masking, although it is constrained by cavity-size selectivity and the comparatively larger excipient mass required per dose. Quantitative comparison of representative drug candidates drawn from the published literature indicates that nanocrystal technology generally affords larger absolute increases in saturation solubility and faster initial dissolution, whereas inclusion complexes offer superior batch-to-batch reproducibility, simpler analytical characterization, and a lower regulatory burden for line extensions. The review concludes that the optimal choice between the two platforms is compound- and context-specific, and that hybrid strategies combining both approaches represent an emerging direction in formulation science.